Key Insights

Highlights

Treatment Research

3 treatments under study, led by Valganciclovir

Related Conditions

Often studied with 4 related conditions

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 100/100

Termination Rate

100.0%

1 terminated out of 1 trials

Success Rate

0.0%

-86.6% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

1 of 0 completed with results

Key Signals

1 with results0

Data Visualizations

Phase Distribution

1Total
Phase 1 (1)

Trial Status

Terminated1

Clinical Trials (1)

Showing 1 of 1 trials
NCT05166577Phase 1Terminated

Nanatinostat Plus Valganciclovir in Advanced EBV+ Solid Tumors and in Combination With Pembrolizumab in EBV+ RM-NPC

Showing all 1 trials

Research Network

Common Treatments

  • Valganciclovir1
  • Pembrolizumab1
  • Nanatinostat1

Active Sponsors

  • Viracta Therapeutics, Inc.1

Top Investigators

Related Conditions

  • Nasopharyngeal Carcinoma1
  • Ebv Related Carcinoma1
  • Ebvrelated Leiomyosarcoma1
  • Ebvrelated Sarcoma1

Activity Timeline